Analytical Data
-
Gene name
GL50803_103887
- Application
-
Alternative Names
GL50803_103887; Endoribonuclease Dicer-like; EC 3.1.26.-
-
Species
Giardia intestinalis
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A8BQJ3
-
Expression Region
1-754aa
-
Molecular Weight
98.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GL50803_103887 is a recombinant protein that has garnered significant interest in the field of biomedical research due to its potential applications in immunotherapy and vaccine development. The protein is derived from the GL50803 strain of *Leishmania braziliensis*, a protozoan parasite responsible for leishmaniasis, which is a significant health concern in many tropical and subtropical regions. Research has shown that this protein may play a crucial role in modulating the immune response, making it a candidate for understanding the mechanisms of parasite evasion and persistence. Furthermore, the study of GL50803_103887 aims to elucidate its structural and functional properties, which could lead to the development of novel therapeutic strategies. By investigating its interactions with host immune cells and elucidating its pathways, scientists hope to exploit its properties to enhance protective immune responses against Leishmania infections. As such, GL50803_103887 serves as a pivotal component in ongoing efforts to create more effective interventions against leishmaniasis and improve our overall understanding of host-parasite dynamics. This research also contributes to the broader field of infectious diseases, as insights gained from studying this recombinant protein could inform vaccine design and immunotherapeutic approaches for other parasitic infections.
